WuXi AppTec
Search results
Provided as either a standalone service offering or as part of our integrated CMC development platforms, WuXi Biologics provides extensive expertise and industry-leading timelines for cell line engineering and strain development across a wide range of biotherapeutics.
WuXi Biologics is a global Contract Research Development and Manufacturing Organization (CRDMO) that provides open-access, integrated technology platforms for biologics drug development.
$Provided as either a standalone service offering or as part of our integrated CMC development platforms, WuXi Biologics provides extensive expertise and industry-leading timelines for cell line engineering and strain development across a wide range of biotherapeutics.
Jul 21, 2022 · SINGAPORE - Chinese companies WuXi Biologics and WuXi AppTec will be investing up to $4 billion in total in Singapore to grow their research and development (R&D) and manufacturing...
微生物. 大肠杆菌及酵母表达系统，一体化CMC开发及cGMP生产微生物发酵平台. 质量. 通过FDA, EMA 和 NMPA认证的一流质量体系. 病毒. 全球化一站式CMC开发,多个在建或已投产的cGMP基地用于生产病毒产品及疫苗. 全球布局. 预计到2026年后，公司在中国、爱尔兰、美国、德国和新加坡规划的生物制药生产基地合计产能将超过58万升。 美国. 爱尔兰. 德国. 新加坡. 中国. 卓越的质量标准. 我们提供符合或超越全球法规标准的质量保证、质量控制与运营体系。 药明生物卓越的质量体系已被多个全球监管机构认证，为多种生物制剂和疫苗的生产护航。 了解详情. 时间截至2023年12月. 15. 个. 获GMP认证的生产厂. 21. 项. 来自全球不同监管机构的检查. 33次. 次.
Our Company: WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations...
Jul 21, 2022 · WuXi Bio is laying out $1.4 billion over the next 10 years to beef up research and development plus large-scale drug substance and drug product manufacturing in Singapore. The upgrade is...
